Protein synthesis inhibitors Flashcards
Clindamycin mechanism of action
Inhibits protein synthesis by binding exclusively to the 50S ribosomal subunit
Binds in close proximity to macrolides and Quinupristin/Daltopristin (Synercid®)– may cause competitive inhibition
clindamycin binding site
50S ribosomal subunit
is clindaycin bactericidal or bacteriostatic
bacteriostatic typically but bactericidal at high concentrations
Clindamycins main mechanism of resistance
Altered target sites – encoded by the erm gene, which alters 50S ribosomal binding site; confers high level resistance to macrolides, clindamycin and Synercid® (MLSb resistance)
erm gene
alters 50S ribosomal binding site; confers high level resistance to macrolides, clindamycin and Synercid® (MLSb resistance)
mef gene
encodes for an efflux pump that pumps macrolides out of the cell but NOT clindamycin
Confers low level resistance to macrolides, but clindamycin still remains active
clindamycin’s spectrum of activity
gram + aerobes (MSSA, some MRSA and Streps not PRSP )
anaerobes: including peptostreptococcus, clostridium (except C. diff)
and a few others
clindamycin absorption
good bioavailability both IV and PO
Rapidly and completely absorbed (90%); food has minimal effect on absorption
clindamycin’s distribution
Good serum concentrations with both formulations
Good tissue penetration including bone; minimal CSF penetration
Clindamcin’s elmination
Clindamycin primarily metabolized by the liver (85%); enterohepatic cycling
Half-life is 2.5 to 3 hours (dosed 6 to 8 hrs)
Clindamycin is NOT removed during hemodialysis (no renal adjustments)
clindamycin clinical uses
Anaerobic Infections OUTSIDE of the CNS
Pulmonary, intraabdominal, pelvic, diabetic foot and decubitus ulcer infections
Skin & Soft Tissue Infections (good gram+ but pcn might be better)
PCN-allergic patients
Patients with infections due to CA-MRSA
Alternative therapy
C. perfringens, PCP, Toxoplasmosis, malaria, bacterial vaginosis
clindamycin’s adverse effects on the GI system
Gastrointestinal – 3 to 4% (especially with oral formulation)
Nausea, vomiting, diarrhea, dyspepsia
Clostridium difficile colitis (0.01-10%)– one of worst inducers
Ranges from mild - severe diarrhea
Requires treatment with metronidazole or oral vancomycin
GI side effects occur more commonly with oral administration
clindamycin adverse effects
GI
Hepatotoxicity - rare
Elevated transaminases
Allergy – rare (rash)
Hematological abnormalities-neutropenia and thrombocytopenia (rare)
Macrolides that are used clinically
erythromycin, clarithromycin, and azithromycin
erythromycin is the least commonly used due to adverse effects
Macrolide’s mechanism of action
Inhibit protein synthesis by reversibly binding to the 50S ribosomal subunit
Results in suppression of protein synthesis and bacterial growth is halted
are Macrolides bacteriostatic or bactericidal?
bacteriostatic except in high concentrations
Do macrolides have time or concentration depended effects
erythromycin and clarithromycin display time dependent activity
azithromycin is concentration dependent
2 mechanisms of resistance to macrolides
- Active efflux (accounts for 70-80% in US) – mef gene encodes for an efflux pump that pumps the macrolide out of the cell away from the ribosome; confers low level resistance to macrolides
- Altered target sites (primary resistance mechanism in Europe) – encoded by the erm gene which alters the macrolide binding site on the ribosome; confers high level resistance to all macrolides, clindamycin, and Synercid®
Cross-resistance occurs between all macrolides
macrolides spectrum of activity compared to clindamycin
similar gram positive but macrolides also have activity against bacillus and cornynebacterium spp.
clinda has no gram negative aerobe activity but macrolides have some (NOT Enterobacteriaceae)
macrolides have anaerobe and atypical bacteria activity